B
AVIR icon

Bailard’s Atea Pharmaceuticals AVIR Stock Holding History

Bailard’s Portfolio AVIR Stock Details AVIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$74.9K Buy
+16,100
New +$80.1K ﹤0.01% 761
2022
Q1 		– Sell
-24,400
Closed -$218K – 728
2021
Q4 		$218K Buy
+24,400
New +$380K 0.01% 662

Other funds holding AVIR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $176M AUM 123.21% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Bailard's AVIR Position: Q2 2026 in Review

Bailard opened a new position in Atea Pharmaceuticals (AVIR) in Q2 2026: 16,100 shares worth $74.9K. The stake represents ﹤0.01% of the portfolio and ranks #761 among its holdings. This is a return to the name: Bailard previously reported a position in AVIR as recently as Q4 2021.

Bailard first reported a position in AVIR in Q4 2021 and has held it in 2 quarters since. The position peaked at $218K in Q4 2021. 124 funds tracked by Wall St. Rank hold AVIR as of Q2 2026.

  • Bailard held 16,100 shares of Atea Pharmaceuticals worth $74.9K as of Q2 2026.
  • Atea Pharmaceuticals was a new Bailard position in Q2 2026.
  • Atea Pharmaceuticals made up ﹤0.01% of Bailard's portfolio in Q2 2026, its #761 holding.
  • Bailard first reported a position in Atea Pharmaceuticals in Q4 2021 and has held it in 2 quarters since.
  • Bailard's Atea Pharmaceuticals position peaked at $218K in Q4 2021.
  • 124 funds tracked by Wall St. Rank held Atea Pharmaceuticals as of Q2 2026.

Based on Bailard's 13F filing for Q2 2026, filed 30 Jul 2026.